Literature DB >> 22865388

Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.

Kathleen Guglielmino1, Kaleena Jackson, Todd R Harris, Vincent Vu, Hua Dong, Gavin Dutrow, James E Evans, James Graham, Bethany P Cummings, Peter J Havel, Nipavan Chiamvimonvat, Sanda Despa, Bruce D Hammock, Florin Despa.   

Abstract

Glycemic regulation improves myocardial function in diabetic patients, but finding optimal therapeutic strategies remains challenging. Recent data have shown that pharmacological inhibition of soluble epoxide hydrolase (sEH), an enzyme that decreases the endogenous levels of protective epoxyeicosatrienoic acids (EETs), improves glucose homeostasis in insulin-resistant mice. Here, we tested whether the administration of sEH inhibitors preserves cardiac myocyte structure and function in hyperglycemic rats. University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk. Administration of APAU attenuated the progressive increase of blood glucose concentration and preserved mitochondrial structure and myofibril morphology in cardiac myocytes, as revealed by electron microscopy imaging. Fluorescence microscopy with Ca(2+) indicators also showed a 40% improvement of cardiac Ca(2+) transients in treated rats. Sarcoplasmic reticulum Ca(2+) content was decreased in both treated and untreated rats compared with control rats. However, treatment limited this reduction by 30%, suggesting that APAU may protect the intracellular Ca(2+) effector system. Using Western blot analysis on cardiac myocyte lysates, we found less downregulation of sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA), the main route of Ca(2+) reuptake in the sarcoplasmic reticulum, and lower expression of hypertrophic markers in treated versus untreated UCD-T2DM rats. In conclusion, APAU enhances the therapeutic effects of EETs, resulting in slower progression of hyperglycemia, efficient protection of myocyte structure, and reduced Ca(2+) dysregulation and SERCA remodeling in hyperglycemic rats. The results suggest that sEH/EETs may be an effective therapeutic target for cardioprotection in insulin resistance and diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865388      PMCID: PMC3469704          DOI: 10.1152/ajpheart.00154.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  56 in total

1.  Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.

Authors:  Pavan K Battiprolu; Thomas G Gillette; Zhao V Wang; Sergio Lavandero; Joseph A Hill
Journal:  Drug Discov Today Dis Mech       Date:  2010

Review 2.  Switches in cardiac muscle gene expression as a result of pressure and volume overload.

Authors:  K Schwartz; K R Boheler; D de la Bastie; A M Lompre; J J Mercadier
Journal:  Am J Physiol       Date:  1992-03

Review 3.  Diabetic cardiomyopathy, causes and effects.

Authors:  Sihem Boudina; Evan Dale Abel
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

Review 4.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Authors:  John M Seubert; Darryl C Zeldin; Kasem Nithipatikom; Garrett J Gross
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-07-10       Impact factor: 3.072

5.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.

Authors:  Leigh J Ellmers; J W Knowles; H-S Kim; O Smithies; N Maeda; V A Cameron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08       Impact factor: 4.733

6.  Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function.

Authors:  Ketul R Chaudhary; Sri Nagarjun Batchu; Dipankar Das; Mavanur R Suresh; John R Falck; Joan P Graves; Darryl C Zeldin; John M Seubert
Journal:  Cardiovasc Res       Date:  2009-04-28       Impact factor: 10.787

7.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

Review 8.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

9.  Stereospecific activation of cardiac ATP-sensitive K(+) channels by epoxyeicosatrienoic acids: a structural determinant study.

Authors:  Tong Lu; Mike VanRollins; Hon-Chi Lee
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

10.  Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.

Authors:  Bethany P Cummings; Kimber L Stanhope; James L Graham; Denis G Baskin; Steven C Griffen; Cecilia Nilsson; Anette Sams; Lotte B Knudsen; Kirsten Raun; Peter J Havel
Journal:  Diabetes       Date:  2010-07-09       Impact factor: 9.461

View more
  15 in total

1.  Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Authors:  Clothilde Roche; Marie Besnier; Roméo Cassel; Najah Harouki; David Coquerel; Dominique Guerrot; Lionel Nicol; Emmanuelle Loizon; Isabelle Remy-Jouet; Christophe Morisseau; Paul Mulder; Antoine Ouvrard-Pascaud; Anne-Marie Madec; Vincent Richard; Jeremy Bellien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 2.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

3.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

4.  Lower sarcoplasmic reticulum Ca2+ threshold for triggering afterdepolarizations in diabetic rat hearts.

Authors:  Iuliana Popescu; Guo Yin; Sathya Velmurugan; Jeffrey R Erickson; Florin Despa; Sanda Despa
Journal:  Heart Rhythm       Date:  2018-11-07       Impact factor: 6.343

5.  17β-Estradiol Treatment Improves Acetylcholine-Induced Relaxation of Mesenteric Arteries in Ovariectomized UC Davis Type 2 Diabetes Mellitus Rats in Prediabetic State.

Authors:  Md Rahatullah Razan; Farjana Akther; Rifat A Islam; James L Graham; Kimber L Stanhope; Peter J Havel; Roshanak Rahimian
Journal:  Front Physiol       Date:  2022-06-17       Impact factor: 4.755

6.  Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model.

Authors:  Sanda Despa; Savita Sharma; Todd R Harris; Hua Dong; Ning Li; Nipavan Chiamvimonvat; Heinrich Taegtmeyer; Kenneth B Margulies; Bruce D Hammock; Florin Despa
Journal:  J Am Heart Assoc       Date:  2014-08-21       Impact factor: 5.501

7.  Liraglutide protects cardiac function in diabetic rats through the PPARα pathway.

Authors:  Qian Zhang; Xinhua Xiao; Jia Zheng; Ming Li; Miao Yu; Fan Ping; Tong Wang; Xiaojing Wang
Journal:  Biosci Rep       Date:  2018-02-12       Impact factor: 3.840

Review 8.  A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes.

Authors:  Emily J Cox; Susan A Marsh
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

9.  Hyperamylinemia Increases IL-1β Synthesis in the Heart via Peroxidative Sarcolemmal Injury.

Authors:  Miao Liu; Nirmal Verma; Xiaoli Peng; Sarah Srodulski; Andrew Morris; Martin Chow; Louis B Hersh; Jing Chen; Haining Zhu; Mihai G Netea; Kenneth B Margulies; Sanda Despa; Florin Despa
Journal:  Diabetes       Date:  2016-06-22       Impact factor: 9.461

10.  Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice.

Authors:  Ya-Jun Gui; Tao Yang; Qiong Liu; Cai-Xiu Liao; Jing-Yuan Chen; Ya-Ting Wang; Jia-Hui Hu; Dan-Yan Xu
Journal:  Oncotarget       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.